SHIFT Newsroom · UK

Prostate cancer screening: what October’s debate means for PSA testing

MPs debated prostate screening on 26 October. The minister said PSA-testing policy had not changed; England’s targeted programme is planned for 2027.

October’s parliamentary debate brought prostate screening back into focus. It did not announce a screening programme for every man.

In the debate on 26 October 2026, the minister said PSA-testing policy had not changed and that men concerned about prostate cancer, including those without symptoms, could discuss PSA testing with their GP. She emphasised informed choice about possible benefits and harms. [1]

What is planned in England

The minister restated plans for a targeted programme from 2027. It is intended for eligible men aged 45 to 61 with a BRCA2 gene variant and the specified family history of prostate, breast, pancreatic or ovarian cancer. This follows the government’s June announcement; October’s debate was not its launch. [1,2]

The debate also covered research into screening other higher-risk groups. Calls for wider screening are different from an agreed, available NHS programme.

What a PSA test can tell you

PSA is a blood marker that can help investigate prostate problems. A raised result does not by itself diagnose cancer. Screening can lead to further investigations and can identify cancers that would never have caused harm, which is why benefits and harms both matter. [2]

A useful next step

For more testing context, read SHIFT’s blood-test information.

Sources and evidence

1. Hansard — Prostate Cancer Screening, debate 26 October 2026; ministerial response checked.

2. House of Commons Library — Prostate cancer screening, published 20 October 2026.

← Back to SHIFT Newsroom